Navigation Links
Researchers Design Promising Cancer Drug
Date:3/7/2008

It activates p53 tumor-suppressor function without causing DNA damage

FRIDAY, March 7 (HealthDay News) -- A drug that targets a protein interaction involved in many types of cancer has been created by University of Michigan researchers.

In cell cultures, the small-molecule inhibitor MI-219 was highly effective at preventing the tumor-suppressor function of the protein p53 from being blocked in the presence of a protein called MDM2.

In animals with human cancer, MI-219 completely inhibited tumor growth and appeared to cause no severe side effects.

"For more than 10 years, scientists have searched for ways to block p53 inhibition, but with little success. Our study clearly shows that this can be done," study author Shaomeng Wang, a professor of medicine at the U-M Medical School and co-director of the molecular therapeutics program at the U-M Comprehensive Cancer Center, said in a prepared statement.

The research was published online this week in the Proceedings of the National Academy of Sciences.

Clinical trials of the drug could begin by the end of 2008. If the drug proves safe and effective in humans, it could potentially be used to treat many kinds of cancer, according to the researchers.

In almost all types of human cancer, p53 is inactivated. About half the time, this is because the protein MDM2 binds to p53 and inhibits the tumor-suppressor function of p53. In other cases, p53 dysfunction is due to a missing or mutated gene.

"Many traditional cancer drugs also activate p53, but they do so by causing DNA damage. They kill not only tumor cells but also normal cells, thus having severe side effects. MI-219 is unique in that it is designed to activate p53 without causing DNA damage, specifically killing tumor cells," Wang said.

The University of Michigan has filed a patent application for MI-219 and its related molecules. The technology has been licensed by Ascenta Therapeutics Inc., which helped fund the study. Wang is a scientific founder of Ascenta, serves as its chief scientific adviser, and is the principal investigator on a research contract from Ascenta to U-M.

More information

The National Cancer Institute has more about cancer.



-- Robert Preidt



SOURCE: University of Michigan, news release, March 3, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Case Western Reserve University researchers identify colorectal cancer gene
2. On a roll: MIT researchers devise new cell-sorting system
3. Einstein researchers genetically engineer immune cells into potent weapons for battling HIV
4. Researchers control growth rate of replacement blood vessels, tissues
5. New protein discovery helps researchers understand autoimmune diseases
6. UF researchers warn parents about dangers of childhood foot burns
7. UCLA researchers find blood stem cells originate and are nurtured in the placenta
8. UCSF researchers validate new model for breast cancer risk assessment in multiple ethnic groups
9. Einstein researchers discover gene mutations linked to longer lifespans
10. U-M researchers ID promising new cancer drug
11. Researchers identify new genetic marker for breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Researchers Design Promising Cancer Drug
(Date:8/16/2017)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... Medical Director of its Sienna Plantation facility. , “We are pleased to announce ... said Dr. Michael (Derek) Caraway, Area Medical Director of First Choice Emergency Room – ...
(Date:8/16/2017)... ... ... inspirational story for those shackled by the chains of a broken life. “God Will ... a woman of great faith and wisdom. She is a great motivational speaker. ... raised in Vero Beach, Florida and has dedicated her life and ministry to letting others ...
(Date:8/15/2017)... ... , ... The first study to report that overall survival was extended for ... team’s findings now published online ahead of print in the Journal of Clinical Oncology, ... Transplant Program at Roswell Park Cancer Institute, was principal investigator for one of the ...
(Date:8/15/2017)... ... August 15, 2017 , ... Progressive Dental, a leading ... on the 2017 Fast 50 list of Fastest Growing Companies in Tampa Bay. The ... area who has shown three consecutive years of growth. For this year’s award, Progressive ...
(Date:8/15/2017)... , ... August 15, 2017 , ... ... supplemental information about a patient’s periodontal disease . This information can be ... establish the therapy endpoint. , The two salivary diagnostic tests, named MyPerioPath® and ...
Breaking Medicine News(10 mins):
(Date:7/26/2017)... LOVELAND, Colo. , July 26, 2017 ... Tristan Guttridge and the Bimini SharkLab to custom design the ... diagnostic images of sharks in their native habitat. In ... for Discovery Channel,s Shark Week, Dr. Guttridge approached ... to take pregnancy diagnosis directly to hammerhead sharks underwater. ...
(Date:7/26/2017)... YORK , July 26, 2017 The ... Annual Prix Galien USA Award Nominees. ... the Prix Galien Award recognizes outstanding biomedical and technology product ... To qualify, each candidate must be U.S. ... last five years and demonstrate tremendous potential to impact human ...
(Date:7/24/2017)... N.Y. , July 24, 2017 IBM (NYSE: ... the Gartner Magic Quadrant for Solid-State Arrays (SSA) for the ... According to Gartner, "Vendors in the Leaders ... and Completeness of Vision. A vendor in the Leaders quadrant ... needed to drive the acceptance of new technologies. These vendors ...
Breaking Medicine Technology: